Cognitive impairment is recognized as an important determinant of outcome in schizophrenia, but mental health services generally have little capacity to provide detailed neuropsychological assessments. Computerized testing would overcome this difficulty, provided that such testing was equivalent to testing by a clinician. Given that negative symptoms can include impaired motivation and attention, it is also important to know whether computerized testing is valid in people with more severe negative symptoms. Our study was designed to compare clinician-administered and computerized testing of two domains commonly impaired in schizophrenia, verbalmemory and verbal fluency. We also evaluated the effect of negative symptoms on performance on com...
Forty-six schizophrenic, 22 bipolar, and 26 normal control subjects were administered negative and p...
Cognitive deficits have been hypothesized to be differentially related to the negative, positive and...
There are currently no regulatory approved pharmacological treatments for cognitive impairment assoc...
Background and Objectives: Studies in patients with schizophrenia have shown a decreased overall cog...
Introduction: Schizophrenia is a severe mental disorder that includes alterations of almost all ment...
Objective: To investigate the association between the Positive and Negative Syndrome Scale (PANSS) c...
Cognitive tasks that are too hard or too easy produce imprecise measurements of ability, which, in t...
Previous research has led to the development of short batteries of tests that efficiently measure th...
Previous research has led to the development of short batteries of tests that efficiently measure th...
The cognitive deficits associated with schizophrenia commonly include impairment in attention, which...
Background Research using neuropsychological testing has demonstrated that patients with schizophren...
Background and Aim: Schizophrenia is a severe psychiatric disorder and characterized by impairments ...
Negative symptoms can be grouped into the two dimensions of diminished expression and apathy, which ...
OBJECTIVE: The authors aimed to delineate the 'common denominators' across a representative number o...
The purpose of this study was to compare the psychometric properties of the Screen for Cognitive Imp...
Forty-six schizophrenic, 22 bipolar, and 26 normal control subjects were administered negative and p...
Cognitive deficits have been hypothesized to be differentially related to the negative, positive and...
There are currently no regulatory approved pharmacological treatments for cognitive impairment assoc...
Background and Objectives: Studies in patients with schizophrenia have shown a decreased overall cog...
Introduction: Schizophrenia is a severe mental disorder that includes alterations of almost all ment...
Objective: To investigate the association between the Positive and Negative Syndrome Scale (PANSS) c...
Cognitive tasks that are too hard or too easy produce imprecise measurements of ability, which, in t...
Previous research has led to the development of short batteries of tests that efficiently measure th...
Previous research has led to the development of short batteries of tests that efficiently measure th...
The cognitive deficits associated with schizophrenia commonly include impairment in attention, which...
Background Research using neuropsychological testing has demonstrated that patients with schizophren...
Background and Aim: Schizophrenia is a severe psychiatric disorder and characterized by impairments ...
Negative symptoms can be grouped into the two dimensions of diminished expression and apathy, which ...
OBJECTIVE: The authors aimed to delineate the 'common denominators' across a representative number o...
The purpose of this study was to compare the psychometric properties of the Screen for Cognitive Imp...
Forty-six schizophrenic, 22 bipolar, and 26 normal control subjects were administered negative and p...
Cognitive deficits have been hypothesized to be differentially related to the negative, positive and...
There are currently no regulatory approved pharmacological treatments for cognitive impairment assoc...